Search
Benzgalantamine
go.drugbank.com/drugs/DB19353ApprovedInvestigational[L51564] Benzgalantamine was approved by the FDA in July 2024 for the treatment of mild-to-moderate dementia in Alzheimer's patients.[L51534,L51564] … [A264454] As a prodrug, benzagalantamine remains inert as it passes through the stomach, thereby avoiding many of the gastrointestinal effects associated with peripheral cholinesterase inhibition.
Human varicella-zoster immune globulin
go.drugbank.com/drugs/DB11621ApprovedInvestigationalThe therapeutic efficacy is proven if administered within 4 days of exposure to varicella zoster virus. … It is prepared from pools of healthy human donors' plasma via anion-exchange column chromatography and was approved in 2012 under the name VariZIG to reduce the disease severity in high-risk patients who
Patisiran
go.drugbank.com/drugs/DB14582ApprovedIt is marketed as Onpattro which is formulated as patisiran within a liposome envelope for better delivery to the liver, where transthyretin is produced. … The approval for Onpattro was granted to Alnylam Pharmaceuticals, Inc. in August of 2018. Onpattro has been granted Fast Track, Priority Review and Breakthrough Therapy, and Orphan Drug designations.
Efanesoctocog alfa
go.drugbank.com/drugs/DB16662ApprovedInvestigational[A257464] Efanesoctocog alfa was designed to have an extended half-life, and to surpass the half-life ceiling to which other forms of recombinant FVIII are subjected due to their association with von Willebrand … To extend the half-life of FVIII, efanesoctocog alfa is fused to dimeric Fc, a D'D3 domain of VWF, and two XTEN polypeptides.
Esculin
go.drugbank.com/drugs/DB13155ApprovedEsculin belongs to the family of Glycosyl Compounds. … ) and in daphnin (the dark green resin of Daphne mezereum).
Evolocumab
go.drugbank.com/drugs/DB09303ApprovedInvestigationalEvolocumab is designed to bind to PCSK9 and inhibit PCSK9 from binding to LDL receptors on the liver surface, resulting in more LDL receptors on the surface of the liver to remove LDL-C from the blood. … Evolocumab is the second PCSK9 inhibitor on the market, first being alirocumab.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawnIt is secreted by the D cells of the islets to inhibit the release of insulin and glucagon, and is also generated in the hypothalamus, where it inhibits the release of growth hormone and thyroid-stimulating … hormones from the anterior pituitary [T28].
Products: İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 FLAKON + 1 ÇÖZÜCÜ AMPULPyrimethamine
go.drugbank.com/drugs/DB00205ApprovedInvestigationalVet approvedOne of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis.
Terpin hydrate
go.drugbank.com/drugs/DB13163ApprovedWithdrawnElixirs of terpin hydrate are still available to patients as prescription medications to be prepared by specialty compounding pharmacies. … data to establish general recognition of the safety and effectiveness of these ingredients".
Remestemcel-L
go.drugbank.com/drugs/DB13973ApprovedInvestigationalWithdrawnThe mesenchymal stem cells are derived from the bone marrow of unrelated and human leukocyte antigen (HLA)–unmatched healthy adult donors and have the ability to differentiate into different tissue cells … It is estimated that the patients with the most severe forms of refractory aGvHD that do not respond to steroid therapy have expected one-year survival rates of only 5% to 30% [L11022].